Member Info for TruthCaller

Yes, for some II to 'punt' a six figure sum, and a new well revered NED to appear ....yes imho!

gla

Moneymunch.....exciting times!

gl

Yes obviously the new NED and II think so too....imho....dyor.

raised by a II.....New very professional board...exciting times.......lot of people on this board it seems are not seeing this.....imho....

gla

Things are moving fast in the right direction here, nothing has changed from my perspective placing had to come but that has now been taken up by a II...very interesting and exciting times here MTFB!

gla

has to be this week i would of thought....massive news when it comes imho gla

433 mil traded so far

Dom Perignon time

mazik...what a beautiful sight....cracking a bottle of the best open tonight...gl mate

errrrrr...up 440%.....hahahaahh

i think youre right mate

Commenting, Bruce Williams, Chairman of Motif Bio, said: "We welcome Chris to the Board as we focus on sourcing an appropriate reverse takeover candidate for Motif Bio. We believe that the Company will benefit from Chris's breadth of knowledge and transactional experience and we will provide shareholders with further updates in due course."

when that next RNS comes to confirm our thoughts .....what a day! Everyman and his dog wants in on this today after doing their research imho...auction again.......gla.

13k trade ...that you topping up mazik? :)

.85 paid!

lovely tight spread

over 320 mil traded so far

MMS cannot contain it, massive buys coming in the millions here.....auction again

back on the move north....we have to be hitting a penny today surely on the back of this news imho....as always dyor

gla

not easy to buy....nearly 300 mil traded so far today.

Motif Bio (MTFB) fundamentals
Motif Bio plc is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA. The Company's lead product candidate is iclaprim. Motif Bio is seeking approval of iclaprim from the U.S. Food & Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). More than 3.6 million patients with ABSSSI are hospitalised annually in the U.S. It is estimated that up to 26% of hospitalized ABSSSI patients have renal impairment. The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication.